Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381575 | 0.89 | KCNH2 (0.40) | KCNH2OPRK1OPRM1 | |
| SCHEMBL3381244 | 0.89 | — | — | |
| SCHEMBL3385537 | 0.87 | LTA4H (0.37) | KCNH2OPRK1OPRM1CHRM2CHRM4 | |
| SCHEMBL3379231 | 0.84 | OPRM1 (0.39) | KCNH2OPRK1OPRM1LTA4HOPRD1 | |
| SCHEMBL3379158 | 0.82 | SETD7 (0.42) | OPRK1OPRM1OPRD1 | |
| SCHEMBL3382441 | 0.81 | ROCK2 (0.35) | KCNH2OPRK1OPRM1CHRM2CHRM4 | |
| SCHEMBL3383406 | 0.78 | SETD7 (0.40) | KCNH2OPRK1OPRM1CHRM2CHRM4 | |
| SCHEMBL3382124 | 0.77 | KCNH2 (0.35) | KCNH2OPRK1OPRM1CHRM2CHRM4 | |
| SCHEMBL3382566 | 0.77 | TERT (0.34) | — | |
| SCHEMBL3383083 | 0.75 | SETD7 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896467-B1 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-01 | — | — | EP | claimed |
| EP-1896467-B1 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-01 | — | — | EP | disclosed |
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | DECORTE BART | 2009-11-05 | — | — | US | disclosed |
| US-7582650-B2 | Tricyclic opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-01 | — | — | US | disclosed |
| EP-1896467-A2 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006138528-A2 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060287297-A1 | TRICYCLIC OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287297-A1 | TRICYCLIC OPIOID MODULATORS | OPRD1, OPRM1, OPRK1 | KCNH2 838/4885OPRK1 3/4885OPRM1 2/4885 |
| US-20090275610-A1 | TRICYCLIC OPIOID MODULATORS | OPRD1, OPRM1, OPRK1 | KCNH2 838/4885OPRK1 3/4885OPRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.